噻托溴铵奥达特罗能倍乐的效果好不好

It is shown to be effective in all stages of COPD; in the early stage of COPD, lung function improves the most compared to tiotropium bromide, olodaterol, and Respimat.

Ingelheim, Germany, May 26, 2015 /PRNewswire/ -- Boehringer Ingelheim releases new data analysis results from the pivotal Phase III TONADO® 1&2 Study 4 (NCT01431274/NCT01431287). Data show that tiotropium bromide, olodaterol and Respimat III can provide lung function benefits for patients with chronic obstructive pulmonary disease (COPD) starting from maintenance treatment, with the greatest benefit in the early stage of the disease.

These latest data analyzes of tiotropium, olodaterol, and repimat are encouraging. Most patients have severely reduced lung function when they first seek treatment," said Roland Buhl, director of the Department of Pulmonary Medicine and Professor of Medicine at Mainz University Hospital in Germany. "In patients with COPD, reduced lung function can lead to shortness of breath, which in turn leads to a vicious cycle of decreased physical activity, worsening of symptoms, and even further loss of exercise capacity. New analysis shows that maintenance treatment with tiotropium, olodaterol and Respimat for the first time in patients starting from the time of COPD diagnosis can help improve lung function. "

Dual-branched Sihehua Rebeimab is based on tiotropium bromide and adds a new long-acting β2 receptor agonist - olodaterol. The two drugs can achieve complementary mechanisms and synergistic effects. The latest GOLD (Global Initiative for the Diagnosis, Treatment and Prevention of COPD) guidelines also clearly point out that bronchodilator combination therapy is more effective than bronchodilator monotherapy in preventing acute exacerbations of COPD.

In addition, TONADO™ study results show that tiotropium bromide, olodaterol, and repimat FDC can provide significant improvements in lung function and health-related quality of life beyond the two drugs alone. These data highlight the potential as a rapid-acting, long-acting, once-daily maintenance treatment option for COPD.

Recommended related hot articles: /newsDetail/83871.html